Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...

The Organon board of directors has approved the deal. The transaction is expected to close in the first quarter of 2026, subject to required regulatory approvals. “I am incredibly proud of the work ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included ...

The MarketWatch News Department was not involved in the creation of this content. The acquisition expands Laborie's obstetrics portfolio and demonstrates the company's commitment to delivering ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...

The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...